Published in Hum Vaccin Immunother on July 13, 2016
Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II. Infect Dis Ther (2017) 0.75
Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I. Infect Dis Ther (2017) 0.75
Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol (2012) 6.05
Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst (2011) 4.69
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol (2009) 4.38
23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet (2000) 4.23
Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. Clin Infect Dis (1997) 3.34
Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis (2009) 3.12
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med (2010) 2.30
Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med (2001) 2.03
2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis (2014) 1.81
Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med (2008) 1.72
Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis (2004) 1.71
Influenza vaccination coverage one year after the A(H1N1) influenza pandemic, France, 2010-2011. Vaccine (2011) 1.60
Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis (2015) 1.52
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine. J Infect Dis (2014) 1.51
Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine (2005) 1.44
Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis (2005) 1.43
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis (2010) 1.37
Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune Defic Syndr (2003) 1.36
Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis (2011) 1.33
The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agent Cancer (2010) 1.32
Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis (2007) 1.27
The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis (1990) 1.25
Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America. Clin Infect Dis (2012) 1.24
Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1999) 1.16
Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis (2005) 1.14
Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis (2001) 1.11
Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS (2007) 1.11
Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill (2008) 1.11
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis (2014) 1.06
Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr (2010) 1.05
The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. HIV Med (2010) 1.05
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis (2011) 1.04
The state of measles and rubella in the WHO European Region, 2013. Clin Microbiol Infect (2014) 1.03
Community-Based Outbreak of Neisseria meningitidis Serogroup C Infection in Men who Have Sex with Men, New York City, New York, USA, 2010-2013. Emerg Infect Dis (2015) 1.02
Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS (2012) 1.01
Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis (2008) 0.97
Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis (2009) 0.97
Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr Infect Dis J (2010) 0.97
Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med (2014) 0.97
Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection. AIDS (2014) 0.96
Guidance on vaccination of HIV-infected children in Europe. HIV Med (2012) 0.95
Comparison of the effects of acute influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts. J Clin Virol (2003) 0.94
Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine (2013) 0.93
Decreasing incidence of herpes zoster in the highly active antiretroviral therapy era. Clin Infect Dis (2013) 0.93
Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. Hum Vaccin Immunother (2012) 0.93
Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART. Vaccine (2009) 0.93
Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr (2012) 0.92
Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis (2015) 0.92
Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. AIDS (1994) 0.92
Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis (2014) 0.91
Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr (2008) 0.90
Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai (2002) 0.90
Hepatitis B and A vaccination in HIV-infected adults: A review. Hum Vaccin Immunother (2015) 0.89
Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety. Vaccine (2014) 0.88
Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis (2011) 0.88
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS (2015) 0.87
Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease. HIV Med (2009) 0.87
Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women. Vaccine (2004) 0.86
Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study. Clin Infect Dis (2007) 0.86
Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals. Vaccine (2001) 0.85
Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PLoS One (2013) 0.84
Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults. AIDS (2013) 0.84
Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. PLoS One (2012) 0.84
Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients. Vaccine (2011) 0.84
Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine (2014) 0.84
Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil. Pediatr Infect Dis J (2015) 0.83
Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users. Clin Infect Dis (2014) 0.83
Long-term persistence of humoral immunity after hepatitis A vaccination in HIV-infected adults. J Acquir Immune Defic Syndr (2011) 0.83
Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients. Vaccine (2014) 0.82
Serologic response to hepatitis B vaccination in HIV-Infected patients with isolated positivity for antibodies to hepatitis B core antigen. Clin Infect Dis (2010) 0.82
Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin (2010) 0.81
Yellow fever vaccine for patients with HIV infection. Cochrane Database Syst Rev (2014) 0.80
High need for MMR vaccination in HIV infected adults in Austria. Vaccine (2014) 0.80
Vaccination coverage and immunity against hepatitis B among HIV-infected patients in South Brazil. Braz J Infect Dis (2015) 0.79
Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults. Vaccine (2012) 0.79
Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine (2012) 0.79
Hepatitis B vaccination and plasma HIV-1 RNA. N Engl J Med (1996) 0.79
[Inadequate vaccination coverage in a French cohort of HIV positive patients]. Med Mal Infect (2010) 0.78
Risk Factors for Serogroup C Meningococcal Disease during Outbreak among Men who Have Sex with Men, New York City, New York, USA. Emerg Infect Dis (2015) 0.78
Prophylactic effect of lamivudine-based antiretroviral therapy on incident hepatitis B virus infection among HIV-infected patients. Clin Infect Dis (2013) 0.78
Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men. Hepatology (2013) 0.78
Diphtheria, tetanus, poliomyelitis, yellow fever and hepatitis B seroprevalence among HIV1-infected migrants. Results from the ANRS VIHVO vaccine sub-study. Vaccine (2015) 0.77
Low tetanus, diphtheria and acellular pertussis (Tdap) vaccination coverage among HIV infected individuals in Austria. Vaccine (2015) 0.77
Fulminant VZV infection in an adult AIDS patient treated with steroids: a case report. J Clin Virol (2014) 0.76
Seasonal influenza vaccination rates in the HIV outpatient study-United States, 1999-2013. Clin Infect Dis (2014) 0.76
Phylogenetic and epidemiological analysis of measles outbreaks in Denmark, 2013 to 2014. Euro Surveill (2015) 0.76
HIV care: A missed opportunity for immunization. Vaccine (2016) 0.76
Disseminated vaccine-strain varicella as initial presentation of the acquired immunodeficiency syndrome: a case report and review of the literature. J Clin Virol (2013) 0.76
Failure of highly active antiretroviral therapy in reconstituting immune response to Clostridium tetani vaccine in aged AIDS patients. J Acquir Immune Defic Syndr (2010) 0.75
Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study. J Infect Dis (2016) 0.75
Immunizations during HIV infection. Curr Opin Infect Dis (1998) 0.75